BioCentury
ARTICLE | Clinical News

Alinia nitazoxanide: Phase II data

November 10, 2008 8:00 AM UTC

In an open-label, Egyptian Phase II trial in 44 treatment-naïve patients with chronic HCV, a 4-week lead-in with twice-daily 500 mg Alinia followed by 36 weeks of Pegasys peginterferon alfa-2a plus A...